Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy

NCT04801329 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

ATTR-CM (Transthyretin Amyloid Cardiomyopathy)

Interventions

DRUG: Vyndamax (tafamidis 61mg)

Sponsor

Pfizer